TheraSense buoyed by continuos glucose monitor:
This article was originally published in Clinica
Executive Summary
TheraSense reports that a pivotal trial of its real-time, continuous glucose monitoring system has produced data to support the product's accuracy and efficacy. The results come from the first 30 participants to complete the trial, says the Alameda, California firm, which plans to submit a premarket approval application for the sensor to the US FDA in the second half of 2003. Patients wore the sensors for consecutive three-day periods over 21 days, generating over 3,500 confirmatory capillary blood glucose measurements. These data were compared with capillary finger-stick samples in a Clarke Grid analysis. Some 96.5% of the paired results fell into Clarke Grid regions A and B.
You may also be interested in...
EU Regulatory Assessors Get AI Boost In Reaching Scientific Decisions
The European Medicines Agency is training scientific staff working for the European medicines regulatory network in how to use a new AI-powered search engine that allows them to easily retrieve information on regulatory precedents.
EU Parliament Stricter Than Council On Medicines And Medical Devices Packaging
The EU Parliament's Environment, Public Health and Food Safety committee takes a compromise position with regards to the Packaging and Packaging Waste Directive. Medicines and medical devices should be exempt, but only until 2035, at which point the European Commission should check whether the development of materials and the recycling process have progressed, and may adjust this exemption accordingly.
Stay Or Exit? Global Health Players Ponder New China Trajectory
It's again the time of year when global CEOs descend on China's capital to discuss strategies. This year, however, the mood is different.